BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Luitpold Announces Temporary Suspension of Distribution and Manufacture of Drug Products


4/22/2011 6:48:27 AM

SHIRLEY, N.Y., April 21, 2011 /PRNewswire/ -- Luitpold Pharmaceuticals, Inc. ("Luitpold") today announced that it has temporarily suspended distribution of all of its drug products manufactured at its Shirley, New York facility and marketed by its American Regent, Inc. subsidiary and Animal Health Division. This action DOES NOT affect products manufactured at its PharmaForce Inc. subsidiary, including its Betamethasone Sodium Phosphate and Betamethasone Sodium Acetate Injectable Suspension, USP. Osteohealth and Regency Therapeutics Division products, including SPRIX® (Ketorolac Tromethamine) Nasal Spray are not affected.

As a result of a recent inspection and a follow-up meeting with FDA on April 14, 2011, Luitpold agreed to temporarily suspend distribution of any drug product manufactured at its Shirley, New York facility. (It had previously suspended the manufacture of its drug products on its own initiative).

Luitpold is in the process of developing a plan, in conjunction with outside consultants and the FDA, that will allow it to resume manufacturing and distribution of its drug products as soon as possible. Luitpold Pharmaceuticals, Inc. will provide further information on its estimated timetable to resume supply of products to the market in the near future.

Luitpold has communicated with the FDA Drug Shortage Staff regarding this issue, and will work with them to address potential shortages of drug products critical to patient health.

Any questions concerning this notice should be directed to the American Regent Customer Service Department at 1-800-645-1706 or the Animal Health Division at 1-800-458-0163.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->